Human obesity LIPIN3 polynucleotide and polypeptide sequences and methods of use thereof

• US 20040018497A1
• Filed: 07/26/2002
• Published: 01/29/2004
• Est. Priority Date: 07/26/2002
• Status: Abandoned Application

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Warden, Craig H.
• Application Number:
  US10/206,618
• Publication Number:
  US 20040018497A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

The present invention relates to human LIPIN3 polynucleotides, which are involved in the control of mammalian body weight. The invention encompasses LIPIN3 polynucleotide sequences, including altered (mutant) LIPIN3 sequences, and fragments thereof, vectors and host cells comprising LIPIN3 polynucleotides, Lipin3 polypeptides, antibodies that specifically bind to Lipin3 polypeptide, arrays comprising LIPIN3 polynucleotides and polypeptides, and purified cells comprising an altered LIPIN3 polynucleotide. The invention also encompasses methods and compositions for the diagnosis and/or treatment of obesity and obesity related diseases, and for the identification of individuals susceptible to such diseases. The invention also encompasses methods of screening for compounds that alter LIPIN3 expression, preferably reducing LIPIN3 expression, and compounds that modulate the activity of the LIPIN3 gene product.

Claims

1. An isolated polynucleotide comprising (a) the sequence shown in Table 8, or its complement;

(b) a polynucleotide that selectively hybridizes to the sequence shown in Table 8 relative to a known polynucleotide;

(c) a region of at least about 15 contiguous nucleotides, said region comprising nucleotide 1904 shown in Table 8;

or (d) a polynucleotide that selectively hybridizes to the sequence shown in Table 8 relative to a known polynucleotide.

2. The polynucleotide of claim 1, wherein the region is at least about 20 contiguous nucleotides.

3. A polynucleotide according to claim 1, said polynucleotide further comprising a detectable label.

4. A polynucleotide according to claim 1, wherein said polynucleotide is immobilized on a surface.

5. A polynucleotide according to claim 1, wherein said polynucleotide is single stranded.

6. A polynucleotide according to claim 1, wherein said polynucleotide is selected from the group consisting of DNA and RNA.

7. A polynucleotide according to claim 1, wherein said polynucleotide is prepared in part by chemical synthesis.

8. A vector comprising the polynucleotide according to claim 1.

9. An expression vector comprising the polynucleotide according to claim 1.

10. A host cell comprising the polynucleotide according to claim 1.

20. A method of detecting a polynucleotide polymorphism associated with obesity, comprising:

detecting a polynucleotide according to claim 1.

21. A method of diagnosing obesity or an obesity-related disorder comprising detecting a polynucleotide according to claim 1.

11. An isolated polypeptide comprising:

a polypeptide comprising (i) a polypeptide having the sequence shown in Table 10;

or (ii) a region consisting at least about 5 contiguous amino acids, wherein said region includes amino acid 634 of Table 10.

12. The polypeptide according to claim 11, wherein the polypeptide includes an epitope.

13. The polypeptide according to claim 11, wherein the polypeptide is immobilized on a solid support.

14. A method for detecting differential expression of a LIPIN3 polynucleotide in a test sample comprising:

detecting a level of expression of (i) a polynucleotide comprising the sequence shown in Table 1;

(ii) a polynucleotide comprising the sequence shown in Table 7B;

or (iii) a region of a polynucleotide having the sequence shown in Table 1 or Table 7B, wherein said region is at least about 10 nucleotides in length.

16. The method of claim 14 or 15, wherein the differential expression is elevated expression.

17. The method of claim 14 or 15, wherein the detecting is measuring the level of an RNA transcript.

18. The method of claim 14 or 15, wherein the detecting is by a method including PCR, TMA, bDNA, NAT, or Nasbau.

19. The method of claim 14 or 15, wherein the polynucleotide is immobilized on a surface.

15. A method for detecting obesity or obesity-related disorders associated with differential expression of a LIPIN3 polynucleotide comprising:

(a) detecting a level of expression of (i) a polynucleotide comprising the sequence shown in Table 1;

(ii) a polynucleotide comprising the sequence shown in Table 7B;

or (iii) a region of a polynucleotide having the sequence shown in Table 1 or Table 7B, wherein said region is at least about 10 nucleotides in length.

22. A method for detecting differential expression of a LIPIN3 polypeptide in a test sample comprising:

detecting a level of expression of (i) a polypeptide comprising the sequence shown in Table 9;

(ii) a polypeptide comprising the sequence shown in Table 7A;

or (iii) a region of the polypeptide shown in Table 9 or Table 7A, wherein the region is at least 10 contiguous amino acids in length.

23. The method of claim 22, wherein the differential expression is overexpression.

24. The method of claim 22, wherein the detecting is by a method including western blotting, mass spectroscopy, ELISA, immunohistochemistry, and capillary electrophoresis.

25. A method of screening for agents that reduce the expression of a LIPIN3 polynucleotide in a test cell sample comprising:

contacting one or more cells possessing LIPIN3 overexpression with an antiobesity drug candidate;

measuring expression of;

(i) a polynucleotide comprising the sequence shown in Table 1;

(ii) a polynucleotide comprising the sequence shown in Table 7B;

or (iii) a region of a polynucleotide having the sequence shown in Table 1 or Table 7B, wherein said region is at least about 15 nucleotides in length;

and determining whether expression of the polynucleotide has decreased.

26. The method of claim 25, wherein an amount of the polynucleotide is measured by detecting mRNA in said sample.

27. The method of claim 26, wherein expression is measured by hybridizing said mRNA to a probe that specifically hybridizes to the polynucleotide.

28. The method of claim 27, wherein said hybridizing is according to a method selected from the group consisting of a Northern blot, a Southern blot, an array hybridization, an affinity chromatography, and an in situ hybridization.

29. The method of claim 27, wherein said probe is a member of a plurality of probes that forms an array of probes.

30. The method of claim 26, wherein the level of expression is measured using a nucleic acid amplification reaction.

31. The method of claim 25, wherein the cell is cultured ex vivo.

32. The method of claim 25, wherein said cell is an adipocyte.

33. The method of claim 25, wherein the test agent is selected from the group consisting of antibody;

protein;

nucleic acid; and

small organic molecule.

34. A method of screening for agents that reduce the expression of a Lipin3 polypeptide in a test cell sample comprising:

contacting one or more cells possessing Lipin3 overexpression with an antiobesity drug candidate;

measuring expression of;

(i) a polypeptide comprising the sequence shown in Table 9;

(ii) a polypeptide comprising the sequence shown in Table 7A;

or (iii) a region of the polypeptide shown in Table 9 or Table 7A, wherein the region is at least 10 contiguous amino acids in length;

and determining whether Lipin3 expression has decreased.

35. The method of claim 34, wherein said measuringing is via a method selected from the group consisting of capillary electrophoresis, a Western blot, mass spectroscopy, ELISA, immunochromatography, and immunohistochemistry.

36. The method according to claim 34, wherein said cell is cultured ex vivo.

37. The method according to claim 34, wherein said cell is an adipocyte.

38. The method according to claim 34, wherein the test agent is selected from the group consisting of antibody;

protein;

nucleic acid; and

small organic molecule.